At present, there is no cure for multiple sclerosis and the management of MS patients requires treatment with disease-modifying agents such as interferon beta (IFNB), glatiramer acetate, natalizumab or immunsuppressants such as mitoxantrone, azathioprine or methotrexate. Here, IFNB1 is linked to myeloid sarcoma.